Genitourinary Radiology

MRI could replace DRE for prostate cancer staging
By Amerigo Allegretto
MRI showed comparable performance to DRE in prostate cancer staging without compromising patient outcomes.
July 15, 2026
Prostate Cancer 400
Blue Earth, UCL dose first patient in Ac-225 PSMA prostate trial
By AuntMinnie.com staff writers
The study is evaluating an investigational alpha-emitting PSMA-targeted radiopharmaceutical in prostate cancer patients.
July 9, 2026
Blue Earth Therapeutics Logo
GE HealthCare, Mayo Clinic begin new theranostics trial in Minnesota
By AuntMinnie.com staff writers
First U.S. site to investigate the StarGuide GX SPECT/CT technology.
July 8, 2026
Atom Nuclear Lab Thumb
Blood-based testing could improve prostate cancer screening with MRI
By Amerigo Allegretto
Adding the Stockholm3 blood-based biomarker test could help improve prostate cancer screening with MRI.
June 22, 2026
Prostate Cancer 400
Experts propose new MRI standards for prostate cancer screening
By Kate Madden Yee
The guidance is intended to provide consensus on the acquisition, interpretation, and reporting of prostate MRI.
June 11, 2026
Am 2016 10 04 11 38 34 158 Prostate 400
Image-guided focal laser ablation effective for prostate cancer
By Amerigo Allegretto
MRI-directed, ultrasound-guided TPLA may be a promising technique to treat prostate cancer while avoiding radical therapies.
June 3, 2026
Preablation, postablation, and recurrence multiparametric MRI scans depict a 63-year-old man treated with transperineal focal laser ablation (TPLA) for localized prostate cancer. Clinical parameters included an initial prostate-specific antigen (PSA) level of 7.2 ng/mL, a Prostate Imaging Reporting and Data System (PI-RADS) grade 4 lesion (red circles) in the right apical peripheral zone, and a maximum tumor length of 5 mm. MRI-guided targeted biopsy confirmed a Gleason score 3+4 prostate cancer tumor. (A) Pre-ablation axial T2-weighted MRI scan and apparent diffusion coefficient (ADC) image shows the apical PI-RADS 4 lesion (circles). (B) Six-month post-ablation axial T2-weighted MRI scan and ADC image show cystic necrosis (arrows). There was no evidence of recurrence; the PSA level was 1.5 ng/mL. (C) One-year after ablation, the patient’s PSA level had increased to 4.3 ng/mL. Axial T2-weighted MRI scan and the ADC image shows a recurrent lesion (blue circles) in the right apical peripheral zone adjacent to the ablation scar. Targeted biopsy confirmed Gleason score 3+4 prostate cancer, which was classified as in-field recurrence of clinically significant prostate cancer and subsequently re-treated with TPLA. In summary, serial multiplanar MRI demonstrates treatment response after TPLA with post-ablation necrosis, followed by MRI-detected IFR confirmed with biopsy at 12-month follow-up. Multiparametric MRI was performed with a 3.0-T MRI scanner (Skyra; Siemens Healthineers) using T2-weighted, diffusion-weighted, and ADC sequences, with gadobenate dimeglumine contrast material administration (Bracco Diagnostics).
Nucs AI and AstraZeneca pursue new response-prediction models
By AuntMinnie.com staff writers
Collaboration focuses on metastatic prostate cancer.
May 29, 2026
Prostate Cancer
DeepHealth secures FDA clearance, CE marking for neuro, prostate AI
By AuntMinnie.com staff writers
The company has won multiple regulatory clearances for neuro, prostate, and lumbar MRI AI.
May 20, 2026
Ai Hand
Cochrane updates 2013 prostate cancer screening review
By Kate Madden Yee
Standard PSA screening has a well-known weakness: it catches many slow-growing cancers that would never have caused harm, Cochrane said.
May 18, 2026
Prostate
VR glasses soothe patients undergoing TRUS-guided prostate biopsy
By Amerigo Allegretto
Prostate biopsy patients who view nature-based video content via VR glasses reported having less anxiety and more comfort.
April 8, 2026
Virtual Reality Goggles2 400
MRI 'fingerprinting' technique characterizes prostate lesions
By Amerigo Allegretto
The technique can differentiate suspicious prostate lesions from clinically insignificant lesions.
April 7, 2026
Representative T2-weighted (T2w) images, apparent diffusion coefficient (ADC) maps, and MR fingerprinting (MRF)-derived T1 and T2 maps obtained from three participants with different histologic types of prostatic lesions. Lesions are circled with dashed lines. Mean values with standard deviations for ADC, T1, and T2 are shown at the bottom of the images. PCa = prostate cancer.
Sclerotherapy spares ovarian reserve without loss of therapeutic efficacy
By Kate Madden Yee
The results offer evidence that supports sclerotherapy as an ovary-sparing alternative to surgery for selected patients.
March 25, 2026
Ovary
Page 1 of 95
Next Page